Pipeline
Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria. Extensive Phase I data have demonstrated that BC-3781 can achieve therapeutically relevant blood and tissue levels in man with excellent tolerability when administered by either oral or intravenous routes. Recent Phase II data have further demonstrated that BC-3781 has efficacy comparable to the gold standard, Vancomycin, and that it has a good safety profile in patients treated for serious skin infections.
Based on these results Nabriva has now successfully achieved proof-of-concept for the systemic use of pleuromutilin antibiotics in man to treat ABSSSI, community-acquired bacterial pneumonia (CABP) and other indications.